Janux Therapeutics and Bristol Myers Squibb (BMS) are developing a tumor-activated therapeutic in an exclusive licensing agreement.

Cellular Origins and Fresenius Kabi have completed the first phase of a CGT manufacturing collaboration announced in October ...

For the fourth consecutive year, Vetter has been recognized by the internationally renowned EcoVadis sustainability ranking, ...

Gannet BioChem, a specialty Contract Development and Manufacturing Organization (CDMO) backed by Boston-based private equity ...

Rentschler Biopharma SE has appointed Detra Glinatsis as Head of Business Development U.S., where she will lead all business ...